5805results about "Dispersion delivery" patented technology

Provided herein are epinephrine spray formulations. Also provided herein are methods of treating anaphylaxis by administering epinephrine spray formulations to subjects in need of such treatment.

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

The invention relates to oral liquid for tonifying kidney and bone and a preparation method thereof, and belongs to the technical field of medicine, the oral liquid contains rhizoma drynariae, polygonum multiflorum, poria cocos, teasel root, radix paeoniae alba, angelica sinensis, codonopsis pilosula, prepared rehmannia root, polygonatum kingianum, fructus lycii, native copper and pericarpium citri reticulatae; the rhizoma drynariae is a product obtained by performing enzymolysis on a whole rhizoma drynariae plant through hemicellulase and pectinase, performing enzymolysis through bromelain and papain and performing enzymolysis through nattokinase; polygonum multiflorum is a product obtained by carrying out enzymolysis on Polygonum multiflorum tuberous roots through hemicellulase and pectinase, then carrying out enzymolysis through bromelain and papain and then carrying out enzymolysis through gelatinase. Polygonatum sibiricum is a product obtained by performing enzymolysis on rhizome of Polygonatum sibiricum through hemicellulase and pectinase, performing enzymolysis through bromelain and papain, and performing fermentation through bacillus licheniformis and saccharomyces boulardii. All the active components are matched for use, kidney function metabolism can be well enhanced, bone mineral density is increased, the treatment course is short, the effect taking speed is high, safety and reliability are achieved, and medication compliance is effectively improved.

The present invention relates to a process for producing a sterile liquid pharmaceutical composition suitable for administration by inhalation comprising ensifentrine particles, wherein the process comprises: (a) heating ensifentrine particles at a temperature of from 100° C. to 220° C. to obtain sterile ensifentrine particles; and (b) combining the sterile ensifentrine particles with a sterile liquid vehicle to produce the sterile liquid pharmaceutical composition suitable for administration by inhalation. A process for producing an ampule comprising the sterile liquid pharmaceutical composition is also described.

The disclosure relates to a particulate composition comprising ensifentrine, wherein the particulate composition further comprises: from greater than 0.00 wt % to 0.60 wt % of 1,3-bis(2-(2-(mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2H-pyrimido [6,1-a]isoquinolin-3(4H)-yl)ethyl)urea (BMIQU) relative to the total weight of ensifentrine; and from 0.00 wt % to 0.50 wt % of a biuret impurity of formula (A) relative to the total weight of ensifentrine. Further disclosed herein are liquid pharmaceutical compositions comprising the particulate composition, and a process for producing the particulate composition are also described.

The invention provides a metal polyphenol nanoparticle, a preparation method thereof and an application of the metal polyphenol nanoparticle in preparation of a medicine for treating acute lung injury, the metal polyphenol nanoparticle is formed by self-assembly of metal ions and polyphenol, the metal ions are selected from Mg < 2 + >, Zn < 2 + >, Mn < 2 + > or Cu < 2 + >, and the polyphenol is selected from Mg < 2 + >, Zn < 2 + >, Mn < 2 + > or Cu < 2 + >. The polyphenol is selected from epigallocatechin gallate (EGCG), caffeic acid (CA), chlorogenic acid (CGA), gallic acid (GA) and luteolin (LUT). The metal polyphenol nanoparticles are used for preparing a medicine for treating acute lung injury induced by sepsis, pneumonia, serious trauma or inhalation injury, and the medicine further comprises a pharmaceutically acceptable carrier. The metal polyphenol nanoparticles provided by the invention are simple in preparation process and high in biological safety, polyphenol and metal ions synergistically enhance the anti-inflammatory and antioxidant activity, and the metal polyphenol nanoparticles are superior to the single use of polyphenol or metal ions.

The present invention relates to a compound for use in treating chronic obstructive pulmonary disease (CORD) in a patient, which compound is ensifentrine or a pharmaceutically acceptable salt thereof, wherein the patient has a blood eosinophil count of < 300 cells / μL.

A compound bacterial powder preparation, and a preparation method therefor and the use thereof. The compound bacterial powder preparation comprises Bifidobacterium animalis, Lactiplantibacillus plantarum and Bacillus coagulans, wherein the deposit number of the Bifidobacterium animalis strain is CGMCC No.25681. The compound bacterial powder preparation can stimulate macrophage RAW264.7 of a mouse to generate cell factors TNF-α and IL-6, thereby enhancing immunity; can significantly enhance the cellular immune function, the humoral immune function and the mononuclear-macrophage function of a mouse, and has the function of enhancing immunity; and can increase the ink propelling rate and has the functional potential of relaxing the bowels.

A method of treating an oxidative stress disease includes orally or intragastrically administering, to a subject in need thereof, a pharmaceutical composition including edaravone with a time interval from a consumption of a meal by the subject in need thereof to an administration of the pharmaceutical composition to the subject in need thereof. The time interval is 8 hours or longer after the consumption of a high-fat meal, the time interval is 4 hours or longer after the consumption of a standard meal, or the time interval is 2 hours or longer after the consumption of a light meal.

Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and / or NTM culture conversion to negative during or after the administration period.

The present invention provides methods, compositions (e.g., eyedrop or spongarion composition), and uses for alleviating and preventing age-associated vitreous degeneration in a mammal, comprising administrating to the mammal in need thereof a therapeutically effective amount of L-ergothioneine, an analog or derivative thereof, or a pharmaceutically acceptable salt, acid, ester, polymer, analog or derivative thereof, as an active ingredient. In particular, L-ergothioneine is capable of scavenging chronic reactive oxygen species directly and radically to mitigate and prevent HA depolymerization and HA decreasing-viscosity in the mammal's vitreous body; and / or improving vitreous liquefaction in the mammal.

A nasal spray device comprises a non-pressurized reservoir for containing a liquid formulation; a spray nozzle; and a manually energizable pump, configured to pressurize a quantity of said liquid formulation and causing the liquid formulation to move through the spray nozzle such that the liquid formulation is discharged from the spray nozzle as an aerosol spray. The spray nozzle comprises a membrane having a plurality of micropores of a substantially identical size below 8 micron and beyond 3 micron through which the liquid formulation passes as the liquid formulation is discharged from the device. Said membrane is configured to release said dose of said liquid formulation in a period of at least 500 milliseconds as a conically shaped plume having an apex. An energy of less than 20 Joule / gram is being dissipated in the liquid to preserve the molecular integrity of macromolecules within the liquid.

Compositions and methods for administering ketone bodies to a subject include beta-hydroxybutyrate complexed with or coupled to at least one amino acid. The compositions and methods cause one or more of: weight loss, weight maintenance, reduced blood glucose level, maintenance of blood glucose level, increased muscle and physical performance, enhanced metabolic and cellular repair, improved detoxification and gut health, targeted bioavailability, sustained release and controlled absorption, increased metabolic efficiency, enhanced cellular uptake, minimized side effects, multifunctional therapeutics, improved focus, improved energy, improved cognitive function, improved mental acuity, treatment of traumatic brain injury, treatment of diabetes, treatment of neurological disorder, treatment of cancer, treatment of inflammatory condition, appetite suppression, anti-aging effects, anti-glycation effects, treatment of epilepsy, treatment of depression, improved performance, improved muscle mass, improved motor function, increased strength, increased metabolism, increased fat loss, increased fat oxidation, improved body composition, and improved mood.

The present invention relates to crystal modifications of 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)-α-[N-((S)-1-carboxypropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine (odevixibat), more specifically crystal modifications 1 and 2 of odevixibat. The invention also relates to a process for the preparation of crystal modification 1 of odevixibat, to a pharmaceutical composition comprising crystal modification 1, and to the use of this crystal modification in the treatment of various conditions as described herein.

Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and / or NTM culture conversion to negative during or after the administration period.

Disclosed is a composition including ammonia and curcumin or curcuminoid, such as an ammonium phenoxide of curcumin. Also disclosed is a method for forming an ammonium phenoxide of curcumin or curcuminoid including dissolving the curcumin or curcuminoid in an ammonia solution. Further disclosed is a method of treating a curcumin-improvable condition including administering an ammonium phenoxide of curcumin or curcuminoid to a subject.

The present disclosure is directed to pharmaceutical compositions comprising a PDE V inhibitor and one or more pharmaceutical excipients or additives wherein the pharmaceutical compositions are in the form of liquid pharmaceutical compositions. The pharmaceutical compositions of the present disclosure are useful for the treatment of diseases or conditions which are treatable by administration of PDE V inhibitor drug such as pulmonary arterial hypertension, erectile dysfunction, etc.

The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.

The present disclosure relates to a compound for use in treating chronic obstructive pulmonary disease (COPD) in a patient, which compound is ensifentrine or a pharmaceutically acceptable salt thereof, wherein the patient has a blood eosinophil count of <300 cells / μL, <150 cells / μL, or <100 cells / μL.

The invention provides compositions comprising a source of protein and a urolithin. The invention also provides uses and methods associated with, or making use of the compositions, such as a medicament, dietary supplement, functional food or medical food and in the treatment and / or prophylaxis of a muscle-related pathological condition. The invention also provides kits comprising urolithin and protein.

Apparatus, methods, and systems for delivery and administration of pharmaceutical, therapeutic and cosmetic substances to users. The method includes providing a removable capsule having an atomizer, inserting the removable capsule in a channel of a base unit of a device. The channel is in fluid communication with a mixing chamber of the base unit, and the base unit defines openings on the base unit configured to receive a portion of a conduit and a removable air mover unit. Further, the method includes dispensing, using the atomizer, the at least one medication from the removable capsule to the mixing chamber of the base unit, and using the removable air mover unit, causing air and the at least one medication within the mixing chamber to be conveyed from the mixing chamber to the conduit such that air and the at least one medication dispensed from the removable capsule exits the conduit.

The disclosure relates to a particulate composition comprising ensifentrine, wherein the particulate composition further comprises: from greater than 0.00 wt % to 0.60 wt % of 1,3-bis(2-(2-(mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2H-pyrimido[6,1-a]isoquinolin-3(4H)-yl)ethyl)urea (BMIQU) relative to the total weight of ensifentrine; and from 0.00 wt % to 0.50 wt % of a biuret impurity of formula (A) relative to the total weight of ensifentrine. Further disclosed herein are liquid pharmaceutical compositions comprising the particulate composition, and a process for producing the particulate composition are also described.

The invention belongs to the technical field of biological medicines, and particularly relates to a pyruvate preparation for treating asthma and a preparation method of the pyruvate preparation. The pyruvate preparation is prepared from the following components in parts by weight: 10 to 12 parts of pyruvate, 10 to 12 parts of sodium chloride, 0.5 to 1 part of citric acid and 500 parts of water for injection. The pH value of the pyruvate preparation is 6 to 7. The pyruvate preparation is used for daily management of asthma patients, the purpose of inhibiting asthma is achieved by controlling increase of the number of inflammatory cells such as eosinophilic granulocytes and reducing inflammatory reaction, the effect of the pyruvate preparation is close to that of similar hormone medicine dexamethasone, and the effect of the pyruvate preparation is improved while the treatment purpose is achieved. The dependence and side effects of patients on hormone drugs are reduced.

The disclosure relates to a particulate composition comprising ensifentrine, wherein the particulate composition further comprises: from greater than 0.00 wt % to 0.60 wt % of 1,3-bis(2-(2-(mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2H-pyrimido[6,1-a]isoquinolin-3(4H)-yl)ethyl)urea (BMIQU) relative to the total weight of ensifentrine; and from 0.00 wt % to 0.50 wt % of a biuret impurity of formula (A) relative to the total weight of ensifentrine. Further disclosed herein are liquid pharmaceutical compositions comprising the particulate composition, and a process for producing the particulate composition are also described.

Disclosed are aqueous formulations comprising urolithins particularly water-based formulations comprising urolithins and maltodextrin. Also disclosed are compositions for admixture with water, methods for the preparation of such aqueous formulations, and to the uses of such formulations for both the treatment of diseases, disorders and conditions, for example, diseases disorders or conditions characterized by inadequate mitochondrial function and for administration to generally healthy individuals for example, for improving health and improving muscle function and performance.

The present invention relates to a process for producing a sterile liquid pharmaceutical composition suitable for administration by inhalation comprising ensifentrine particles, wherein the process comprises: (a) heating ensifentrine particles at a temperature of from 100° C. to 220° C. to obtain sterile ensifentrine particles; and (b) combining the sterile ensifentrine particles with a sterile liquid vehicle to produce the sterile liquid pharmaceutical composition suitable for administration by inhalation. A process for producing an ampule comprising the sterile liquid pharmaceutical composition is also described.